Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.5 USD | +6.19% | +17.92% | +398.60% |
May. 30 | Scotiabank Starts Janux Therapeutics With Sector Perform Rating | MT |
May. 30 | Certain Pre Funded Warrants of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024. | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+398.60% | 2.77B | C | ||
+43.36% | 54.63B | B- | ||
-5.31% | 39.92B | B | ||
+14.75% | 26.86B | B- | ||
-12.56% | 26.22B | C | ||
-22.45% | 18.78B | B | ||
+25.12% | 12.21B | B+ | ||
+0.04% | 12.16B | B+ | ||
+26.04% | 11.94B | C+ | ||
-11.83% | 10.74B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JANX Stock
- Ratings Janux Therapeutics, Inc.